Telomir Pharmaceuticals (NASDAQ:TELO) Issues Earnings Results

Telomir Pharmaceuticals (NASDAQ:TELO) posted its quarterly earnings results on Thursday. The company reported ($0.79) earnings per share (EPS) for the quarter, Zacks reports.

Telomir Pharmaceuticals Stock Performance

Telomir Pharmaceuticals stock traded down $0.06 during trading on Thursday, reaching $1.05. 86,652 shares of the company’s stock were exchanged, compared to its average volume of 126,949. Telomir Pharmaceuticals has a 52-week low of $0.89 and a 52-week high of $2.09. The firm has a market cap of $72.22 million, a price-to-earnings ratio of -3.62 and a beta of -0.24. The company’s 50-day moving average is $1.22 and its two-hundred day moving average is $1.25.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold”.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of America Corp DE boosted its position in shares of Telomir Pharmaceuticals by 283.9% in the fourth quarter. Bank of America Corp DE now owns 14,713 shares of the company’s stock worth $61,000 after buying an additional 10,880 shares during the period. Marshall Wace LLP purchased a new stake in shares of Telomir Pharmaceuticals during the 2nd quarter valued at about $95,000. Qube Research & Technologies Ltd acquired a new position in Telomir Pharmaceuticals during the 2nd quarter worth approximately $33,000. Jane Street Group LLC purchased a new position in Telomir Pharmaceuticals in the 2nd quarter worth approximately $62,000. Finally, Raymond James Financial Inc. boosted its holdings in Telomir Pharmaceuticals by 4,101.9% in the 3rd quarter. Raymond James Financial Inc. now owns 75,340 shares of the company’s stock worth $105,000 after acquiring an additional 73,547 shares during the period.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc (NASDAQ: TELO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited.

The company’s lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling.